10-Q: Sonnet BioTherapeutics Reports Q3 Loss, Announces Merger

Sonnet BioTherapeutics reported increased net losses for the nine months ended June 30, 2025, while advancing its clinical pipeline and announcing a definitive merger agreement with Hyperliquid Strategies Inc.

Summary

• Sonnet BioTherapeutics reported a net loss of $10.4 million for the nine months ended June 30, 2025, significantly higher than the $4.3 million loss for the same period in 2024.
• Collaboration revenue increased to $1.0 million for the nine months ended June 30, 2025, primarily from the Alkem Agreement, compared to $18,626 in the prior year.
• Research and development expenses increased to $6.2 million for the nine months ended June 30, 2025, from $4.5 million in the prior year, driven by clinical trial costs and license fees.
• General and administrative expenses rose to $5.7 million for the nine months ended June 30, 2025, from $4.2 million in the prior year, due to professional fees and the cancellation of accrued bonuses in the prior period.
• Cash on hand as of June 30, 2025, was $0.3 million, with an additional $18.0 million raised in July 2025 through convertible notes, preferred stock, and warrant exercises.
• The company entered into a definitive Business Combination Agreement with Rorschach I LLC and Hyperliquid Strategies Inc. (HSI) on July 11, 2025, under which Sonnet will become a wholly-owned subsidiary of HSI and focus on its biotech assets, while legacy Sonnet stockholders will receive Contingent Value Rights (CVRs).
• Nasdaq confirmed the company's compliance with the minimum stockholders' equity requirement on July 23, 2025, following the recent capital raise.
• The company's most advanced asset, SON-1010, showed partial responses in two of three platinum-resistant ovarian cancer (PROC) patients at the highest dose in the SB221 trial, and dose escalation was completed at 1200 ng/kg.
• The SB101 clinical study of SON-1010 was expanded to evaluate its effect in combination with trabectedin for soft tissue sarcoma, with initial safety and tolerability reported in March 2025.
• The SON-080 program for Chemotherapy-Induced Peripheral Neuropathy (CIPN) was put on hold, but a licensing agreement with Alkem Laboratories Limited was executed for its development and commercialization in India for Diabetic Peripheral Neuropathy (DPN).
• The SON-1210 program is advancing with an investigator-initiated Phase 1b/2a study in pancreatic cancer expected to dose its first patient in H2 calendar year 2025.

Sentiment

Score: 3

Explanation: The sentiment is low due to significant and increasing net losses, persistent negative cash flow, and substantial doubt about the company's ability to continue as a going concern. While there are positive clinical updates and recent capital raises, the financial distress is severe. The announced merger with a company adopting a highly speculative cryptocurrency treasury strategy introduces extreme, unpredictable risks that overshadow any biotech progress and fundamentally alter the investment profile, making the company's future highly uncertain and volatile.

Positives

• SON-1010 demonstrated partial responses in two of three evaluable platinum-resistant ovarian cancer patients at the highest dose (1200 ng/kg) in the SB221 trial.
• The maximum tolerated dose (MTD) for SON-1010 was established at 1200 ng/kg in both SB101 and SB221 trials, indicating a favorable safety profile with transient, mild adverse events and no cytokine release syndrome.
• The SB101, SB102, and SB221 trials have collectively enrolled 99 subjects, with 13 of 24 evaluable monotherapy cancer patients (54%) showing clinical benefit (stable disease at four months), and 5 of 6 patients (83%) at the highest dose showing clinical benefit.
• The company successfully raised $18.0 million in July 2025 through convertible notes, preferred stock, and warrant exercises, significantly improving its cash position.
• Nasdaq confirmed the company's compliance with the minimum stockholders' equity requirement on July 23, 2025, mitigating immediate delisting concerns.
• The Alkem Agreement for SON-080 in India provides $1.0 million in upfront payments and potential additional milestone payments up to $1.0 million, shifting development costs for DPN in India to Alkem.
• The SOC Agreement for SON-1210 will fund an investigator-initiated Phase 1b/2a study in pancreatic cancer, reducing the company's direct development expenses for this program.

Negatives

• The net loss for the nine months ended June 30, 2025, increased significantly to $10.4 million from $4.3 million in the prior year, indicating a worsening financial performance.
• The company incurred recurring losses and negative cash flows from operations since inception, raising substantial doubt about its ability to continue as a going concern.
• Cash on hand at June 30, 2025, was critically low at $0.3 million, necessitating immediate capital raises.
• Other income, primarily from the sale of New Jersey state net operating losses, decreased substantially to $0.7 million for the nine months ended June 30, 2025, from $4.3 million in the prior year, reducing a key non-dilutive funding source.
• The SB211 study for SON-080 in CIPN was put on hold due to business priorities, delaying direct development of this program.
• The SON-3015 development program was placed on hold for expense reduction purposes, indicating financial constraints affecting pipeline progression.
• The New Life Agreement for SON-080 is subject to a 'Give Back Option' negotiation, which could result in the loss of rights in the Exclusive Territory.

Risks

• The company has incurred recurring losses and negative cash flows from operations since inception, and its ability to continue as a going concern is in substantial doubt, requiring significant additional financing.
• Failure to maintain compliance with Nasdaq's continued listing requirements could result in the delisting of common stock, adversely affecting liquidity, trading volume, and the ability to raise capital.
• The completion of the business combination with Hyperliquid Strategies Inc. (HSI) is subject to customary closing conditions, including stockholder approval, and may be delayed or not completed at all, leading to significant costs and business disruption.
• The new HYPE treasury strategy, post-merger with HSI, subjects the company to enhanced regulatory oversight and the highly volatile nature of cryptocurrency prices, which could adversely affect financial results and stock price.
• HYPE and other digital assets are subject to significant legal and regulatory uncertainty; any classification of HYPE as a security could subject the company to additional regulation (e.g., Investment Company Act of 1940) and materially impact business operations.
• The company faces risks relating to the custody of its HYPE holdings, including loss or destruction of private keys, cyberattacks, smart contract vulnerabilities, and potential treatment as a general unsecured creditor in custodian insolvency proceedings.
• The historical financial statements do not reflect the potential variability in earnings from HYPE holdings, as new accounting standards (ASU 2023-08) will require fair value measurement with gains/losses recognized in net income, leading to significant earnings volatility.
• Unrealized fair value gains on HYPE holdings could subject the company to the 15% corporate alternative minimum tax (CAMT) under the Inflation Reduction Act of 2022, potentially resulting in a material cash tax obligation.
• The unregulated nature and lack of transparency of many HYPE trading venues pose risks of fraud, security failures, or operational problems, which could lead to a loss of confidence in HYPE and adversely affect its value.
• The concentration of HYPE holdings limits risk mitigation and enhances inherent risks, meaning significant declines in HYPE price would have a more pronounced impact on financial condition.
• The emergence or growth of other blockchains and associated digital assets could negatively impact the price of HYPE and adversely affect the business.
• HYPE holdings are less liquid than cash and cash equivalents and may not serve as a reliable source of liquidity, especially during market instability, potentially forcing asset sales at a loss.

Future Outlook

The company expects to continue incurring significant expenses and increasing operating losses for the foreseeable future, primarily due to research and development costs for its product candidates. Substantial additional financing will be needed to fund operations beyond February 2026. Future activities include conducting additional clinical trials, discovering and developing new product candidates, acquiring or in-licensing technologies, maintaining intellectual property, hiring personnel, establishing manufacturing and supply chains, seeking regulatory approvals, and building commercialization infrastructure. The company plans to finance operations through equity or debt financings, including its Committed Equity Facility, partnerships, collaborations, or other sources.

Management Comments

• We believe our FHAB technology, for which we received an initial U.S. patent in June 2021 and a continuation of such patent in June 2024, is a distinguishing feature of our biopharmaceutical platform.
• We believe that SON-1010 has the potential to complement that activity by activating the NK and T cells in the TME to secrete more interferon-gamma (IFN), which is considered to be important for anti-tumor control.
• Given the business priorities at the time, the SB211 study (for SON-080 in CIPN) was put on hold.
• Until new clinical data are generated in the DPN indication, we have decided to delay further direct development of this program (SON-080).
• We have elected to place the SON-3015 development program on hold for expense reduction purposes.
• We expect to continue to incur significant expenses and increasing operating losses for at least the next several years.
• We will not generate revenue from product sales, if any, unless and until we receive licensing revenue and/or successfully complete clinical development and obtain regulatory approval for our product candidates.
• We expect that our expenses and capital requirements will increase in connection with our ongoing activities, particularly if and as we conduct additional clinical trials for product candidates.
• We believe our cash of $0.3 million at June 30, 2025, in addition to $10.5 million raised in July 2025 through the sale of convertible notes, preferred stock and warrants and the exercise of certain outstanding warrants, will fund our projected operations into February 2026.

Industry Context

Sonnet BioTherapeutics operates in the highly competitive and capital-intensive clinical-stage biotechnology sector, specifically focusing on oncology and peripheral neuropathies. The company's FHAB platform aims to improve drug delivery and extend activity duration, addressing common challenges in cytokine therapy. The collaboration with Roche for SON-1010 and the licensing agreement with Alkem for SON-080 reflect a common industry strategy for clinical-stage companies to de-risk development and secure funding through partnerships. The announced merger with Hyperliquid Strategies Inc. and the subsequent adoption of a cryptocurrency (HYPE) treasury strategy is a highly unusual and potentially disruptive move for a biotech company, diverging significantly from traditional industry financial management practices and introducing novel risks.

Comparison to Industry Standards

• Clinical-stage biotechnology companies typically incur significant R&D expenses and operating losses, consistent with Sonnet's financial performance. However, Sonnet's net loss for the nine months ended June 30, 2025, of $10.4 million represents a substantial increase compared to the prior year, indicating an accelerating cash burn rate.
• The company's cash position of $0.3 million at quarter-end, prior to the July 2025 capital raise, was significantly below industry averages for companies with active clinical programs, highlighting severe liquidity constraints.
• The reliance on equity financings and the Committed Equity Facility (ChEF) is a common funding mechanism for pre-revenue biotechs, but the frequency and size of recent raises (October 2023, November 2024, December 2024, July 2025) suggest persistent and substantial capital needs.
• The decision to put the SON-080 CIPN study on hold due to 'business priorities' and the 'Give Back Option' negotiation with New Life for DPN rights indicate challenges in advancing certain pipeline assets, which is not uncommon but can signal strategic shifts or resource limitations.
• The adoption of a cryptocurrency treasury strategy, as planned by the acquiring entity Hyperliquid Strategies Inc., is a radical departure from standard financial practices in the biotech industry. This introduces a new layer of market, regulatory, and operational risks that are not typically associated with biotech companies, making direct comparisons to traditional biotech financial benchmarks difficult and potentially misleading.

Management Changes

Corporate Governance

Legal Proceedings

• No reportable legal proceedings or material developments to previously reported legal proceedings during the three-month period ended June 30, 2025.

Related Party Transactions

• Dr. Richard Kenney, the company's Chief Medical Officer, participated in the July 2025 private placement, purchasing convertible notes for a principal amount of $0.2 million and warrants to purchase up to an aggregate of 86,505 shares of common stock.

Stakeholder Impact

• Shareholders face significant dilution from multiple recent equity offerings and warrant exercises, as well as potential future dilution due to ongoing capital needs.
• Legacy Sonnet stockholders will receive Contingent Value Rights (CVRs) tied to the potential future value of the company's biotech assets post-merger, providing a potential upside but also uncertainty.
• The company's ability to continue as a going concern remains in substantial doubt, posing a risk to all stakeholders.
• The new HYPE treasury strategy introduces unprecedented volatility and regulatory risks for investors, fundamentally changing the risk profile of the investment.
• Employees and management may experience uncertainty related to the merger and the new strategic direction, though an employment agreement for the Interim CEO has been noted.

Next Steps

• Negotiate and mutually agree on terms for the 'Give Back Option' with New Life Therapeutics Pte, Ltd. regarding SON-080 rights.
• Alkem Laboratories Limited is expected to initiate a Phase 2 clinical trial for SON-080 in Diabetic Peripheral Neuropathy (DPN) in H2 calendar year 2025.
• Topline efficacy data for the SON-1010 monotherapy Phase 1 trial (SB101) in solid tumors is expected in H1 calendar year 2025.
• RP2D (Recommended Phase 2 Dose) safety and topline efficacy data for the SON-1010 in combination with atezolizumab Phase 1b/2a trial (SB221) in PROC is expected in H2 calendar year 2025.
• Topline efficacy data for the SON-1010 with trabectedin Phase 1 trial in soft-tissue sarcoma is expected by the end of calendar 2025.
• Preparations for the full IND submission package for SON-1210 are underway, following positive FDA feedback on the pre-IND package.
• The Sarcoma Oncology Center (SOC) is expected to initiate SON-1210 dosing in study SOC-241 (investigator-initiated Phase 1b/2a study in pancreatic cancer) in H2 calendar year 2025.
• The business combination with Hyperliquid Strategies Inc. (HSI) is expected to close in the second half of calendar 2025, subject to customary closing conditions, including stockholder approval.
• The company will continue to seek additional capital through equity or debt financings, partnerships, collaborations, or other sources to fund operations beyond February 2026.

Key Dates

Recommendation

Despite some positive clinical trial progress for SON-1010 and recent capital raises, the company's financial position is severely distressed, evidenced by a substantial increase in net losses and persistent negative cash flow, leading to a going concern doubt. The most significant factor driving a 'strong sell' recommendation is the announced merger with Hyperliquid Strategies Inc. and the subsequent adoption of a cryptocurrency (HYPE) treasury strategy. This move introduces an entirely new, highly speculative, and volatile risk profile completely unrelated to the core biotech business. The inherent risks of cryptocurrency, including extreme price fluctuations, regulatory uncertainty, custody issues, and potential tax implications (CAMT), are profound and unpredictable. This strategic pivot fundamentally undermines the investment thesis for a biotech company, making it an exceptionally high-risk proposition with potential for significant capital loss, irrespective of clinical progress.

Keywords

Biotechnology, Oncology, Clinical Stage, Biologics, FHAB, SON-1010, IL-12, SON-080, IL-6, SON-1210, IL-15, Cancer Treatment, Neuropathy, SEC Filing, 10-Q, Merger, Hyperliquid Strategies, Cryptocurrency, HYPE, Nasdaq Listing, Clinical Trials, Drug Development, Going Concern